RT Journal Article
T1 Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study.
A1 Mora-Ortiz, Marina
A1 Alcala-Diaz, Juan F
A1 Rangel-Zuñiga, Oriol Alberto
A1 Arenas-de Larriva, Antonio Pablo
A1 Abollo-Jimenez, Fernando
A1 Luque-Cordoba, Diego
A1 Priego-Capote, Feliciano
A1 Malagon, Maria M
A1 Delgado-Lista, Javier
A1 Ordovas, Jose M
A1 Perez-Martinez, Pablo
A1 Camargo, Antonio
A1 Lopez-Miranda, Jose
K1 Diabetes
K1 Insulin resistance
K1 Metabolomics
K1 Prospective human study
AB Type 2 diabetes mellitus (T2DM) is one of the most widely spread diseases, affecting around 90% of the patients with diabetes. Metabolomics has proven useful in diabetes research discovering new biomarkers to assist in therapeutical studies and elucidating pathways of interest. However, this technique has not yet been applied to a cohort of patients that have remitted from T2DM. All patients with a newly diagnosed T2DM at baseline (n = 190) were included. An untargeted metabolomics approach was employed to identify metabolic differences between individuals who remitted (RE), and those who did not (non-RE) from T2DM, during a 5-year study of dietary intervention. The biostatistical pipeline consisted of an orthogonal projection on the latent structure discriminant analysis (O-PLS DA), a generalized linear model (GLM), a receiver operating characteristic (ROC), a DeLong test, a Cox regression, and pathway analyses. The model identified a significant increase in 12 metabolites in the non-RE group compared to the RE group. Cox proportional hazard models, calculated using these 12 metabolites, showed that patients in the high-score tercile had significantly (p-value  Our study identified 12 endogenous metabolites with the potential to predict T2DM remission following a dietary intervention. These metabolites, combined with clinical variables, can be used to provide, in clinical practice, a more precise therapy. 
PB BioMed Central
YR 2022
FD 2022-09-12
LK http://hdl.handle.net/10668/20310
UL http://hdl.handle.net/10668/20310
LA en
NO Mora-Ortiz M, Alcala-Diaz JF, Rangel-Zuñiga OA, Arenas-de Larriva AP, Abollo-Jimenez F, Luque-Cordoba D, et al. Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study. BMC Med. 2022 Oct 27;20(1):373
DS RISalud
RD Jul 3, 2025